We honor 100 of the leading innovators in pathology and laboratory medicine by celebrating their success at the cutting edge of the field.
Not every assay that trials well is practical for implementation in daily practice. How can we tell which ones are, and whose responsibility is it?
A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.
David L. Rimm
David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.
Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment
An efficient alternative to pap-HPV tests could lie with ddPCR and a ccfDNA assay
Antonia R. Sepulveda
New collaborative guidelines for molecular biomarker testing in colorectal cancer
An examination of domain-specific companion diagnostic testing
An industry pathologist’s perspective on developing a companion diagnostic
Henrik Winther and Hans Christian Pedersen
Industry and regulators collaborate to harmonize or consolidate PD-1/PDL-1 assays
How liquid biopsy and next-generation sequencing fit into the pathology lab of the future
Send me the latest from The Pathologist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.